Affiliation:
1. School/Hospital of Stomatology, Lanzhou University, Lanzhou, Gansu, China
2. Clinical Research Center for Oral Diseases, Lanzhou, Gansu, China
Abstract
Background:
Evodiamine (EVO) is an alkaloid extracted from the dried and nearly
ripe fruits of Euodia rutaecarpa and used as an anti-cancer, anti-inflammatory and anti-obesity
agent. However, robust evidence of preclinical experiments has been lacking so far. Therefore, the
purpose of this article was to investigate the effect of EVO in combination with other treatments
on tumors in animal experiments.
Methods:
A systematic review and meta-analysis were conducted to assess the anti-tumor effect
of evodiamine-combined therapy. The search engine and electronic databases included PubMed,
Scopus, China Knowledge Resource Integrated Database (CNKI), and SinoMed. The research
method was based on the PRISMA checklist.
Results:
A total of 7 studies and 108 animals were included. As a result, EVO combined therapy
was found to be more effective than EVO monotherapy. The SMD was -25.64(95% CI: -5.77
-3.13) in tumor growth. In tumor weight, the SMD was -8.91(95% CI: -16.37, -1.44).
Conclusion:
EVO has the potential to alleviate the toxicity of chemotherapeutic agents, which increases the translatability to the clinical situation.
Publisher
Bentham Science Publishers Ltd.